{"id":17541,"date":"2026-07-03T12:35:32","date_gmt":"2026-07-03T07:05:32","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=17541"},"modified":"2026-07-06T12:35:39","modified_gmt":"2026-07-06T07:05:39","slug":"epidiolex-vs-fintepla","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla","title":{"rendered":"EPIDIOLEX and FINTEPLA in 2026: Commercial Anchors in a Precision DEE Pipeline"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_85 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a84e4eb8d55f\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a84e4eb8d55f\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla\/#Better_Efficacy_EPIDIOLEX_or_FINTEPLA\" >Better Efficacy: EPIDIOLEX or FINTEPLA?&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla\/#Commercial_Expansion_Beyond_the_US\" >Commercial Expansion Beyond the US<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla\/#The_Next_Wave_of_Competition_in_the_DEE_Market\" >The Next Wave of Competition in the DEE Market<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Developmental and epileptic encephalopathies (DEEs) have evolved from symptom control toward precision neurology, with the market anchored by <strong>EPIDIOLEX <\/strong>(cannabidiol, Jazz Pharmaceuticals), initially approved in the US in 2018 for Dravet syndrome and Lennox\u2013Gastaut syndrome (LGS) and later expanded to tuberous sclerosis complex (TSC) in 2020, and <strong>FINTEPLA <\/strong>(fenfluramine, UCB), approved for Dravet syndrome in 2020 and LGS in 2022. The market has further expanded with <strong>ZTALMY <\/strong>(ganaxolone, Marinus Pharmaceuticals), approved in 2022 as the first therapy specifically indicated for <a href=\"https:\/\/www.delveinsight.com\/report-store\/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market\">CDKL5 deficiency disorder<\/a>, reinforcing the shift toward mechanism-based and syndrome-specific treatment. Looking ahead, antisense oligonucleotides, gene-based therapies, and targeted small molecules are expected to further transform the DEE treatment landscape.<\/p>\n\n\n\n<p>EPIDIOLEX and FINTEPLA are locking horns in the rare DEE segment, with EPIDIOLEX currently leading in terms of sales. The unexpectedly strong uptake and high sales of EPIDIOLEX are mainly due to the first-mover advantage of a novel class in this space, which only had antiepileptic drugs (AEDs) used in combination. EPIDIOLEX achieved blockbuster status in 2025, with net product sales of approximately <strong>USD 1.1 billion<\/strong>, reflecting <strong>9%<\/strong> year-over-year growth from 2024. By contrast, FINTEPLA is far behind, with global revenues rising <strong>50%<\/strong> to <strong>USD 368 million <\/strong>in 2024 and further increasing to <strong>USD 483 million<\/strong> in 2025. FINTEPLA continues to trail EPIDIOLEX owing to its later market entry, a narrower initial label limited to Dravet syndrome, and comparatively shorter physician experience and market penetration.\u00a0\u00a0<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"388\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/FINTEPLA-and-EPIDIOLEX-Global-Sales-2022-2025-1024x388.webp\" alt=\"FINTEPLA-and-EPIDIOLEX-Global-Sales Assessment\" class=\"wp-image-35647\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/FINTEPLA-and-EPIDIOLEX-Global-Sales-2022-2025-1024x388.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/FINTEPLA-and-EPIDIOLEX-Global-Sales-2022-2025-300x114.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/FINTEPLA-and-EPIDIOLEX-Global-Sales-2022-2025-150x57.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/FINTEPLA-and-EPIDIOLEX-Global-Sales-2022-2025-768x291.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/FINTEPLA-and-EPIDIOLEX-Global-Sales-2022-2025-1536x582.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/FINTEPLA-and-EPIDIOLEX-Global-Sales-2022-2025.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Better_Efficacy_EPIDIOLEX_or_FINTEPLA\"><\/span><strong>Better Efficacy: EPIDIOLEX or FINTEPLA?&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Among EPIDIOLEX and FINTEPLA, both drugs have significant overall efficacy and safety; however, when comparing their efficacy in Dravet syndrome, FINTEPLA&#8217;s response rate was 4 times higher, and in LGS, it was 3 times higher than placebo. In contrast, EPIDIOLEX reduced the seizure frequency by three times for Dravet syndrome and by two times for LGS compared to placebo. Also, the efficacy numbers for FINTEPLA were lower in LGS than in Dravet syndrome, with a 60%+ reduction. Thus, FINTEPLA beats EPIDIOLEX in terms of efficacy, and we believe that FINTEPLA\u2019s efficacy in <a href=\"https:\/\/www.delveinsight.com\/report-store\/dravet-syndrome-market\">Dravet patients<\/a> is much higher than that of those suffering from LGS.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"305\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/Market-Share-Distribution-of-DEE-by-Therapies-in-the-7MM-2026-1024x305.webp\" alt=\"Market-Share-Distribution-of-DEE-by-Therapies-in-the-7MM-in-2026\" class=\"wp-image-35649\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/Market-Share-Distribution-of-DEE-by-Therapies-in-the-7MM-2026-1024x305.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/Market-Share-Distribution-of-DEE-by-Therapies-in-the-7MM-2026-300x89.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/Market-Share-Distribution-of-DEE-by-Therapies-in-the-7MM-2026-150x45.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/Market-Share-Distribution-of-DEE-by-Therapies-in-the-7MM-2026-768x229.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/Market-Share-Distribution-of-DEE-by-Therapies-in-the-7MM-2026-1536x458.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/Market-Share-Distribution-of-DEE-by-Therapies-in-the-7MM-2026.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Commercial_Expansion_Beyond_the_US\"><\/span><strong>Commercial Expansion Beyond the US<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The European <a href=\"https:\/\/www.delveinsight.com\/report-store\/developmental-and-epileptic-encephalopathies-dee-market\">DEE treatment market<\/a> has become increasingly favorable for both EPIDIOLEX (EPIDYOLEX in Europe) and FINTEPLA, although reimbursement negotiations continue to shape the pace of commercial uptake in individual countries. EPIDYOLEX has established a broad commercial presence across major European markets following its EU approval in 2019 and subsequent reimbursement agreements, while FINTEPLA has also expanded steadily after receiving approvals for Dravet syndrome and LGS. Nevertheless, differences in national pricing and reimbursement frameworks continue to create variability in market access and adoption across Europe.<\/p>\n\n\n\n<p>In Japan, FINTEPLA has significantly strengthened its position, securing approvals for Dravet syndrome (2022) and LGS (2024) through <strong>UCB&#8217;s partnership with Nippon Shinyaku<\/strong>, providing access across both of its major approved indications. In contrast, EPIDIOLEX remains unapproved in Japan following its 2024 Phase III trial, which failed to meet the primary efficacy endpoint. However, numerical improvements in seizure outcomes and a favorable safety profile have prompted <strong>Jazz Pharmaceuticals<\/strong> to continue pursuing regulatory approval in collaboration with <strong>Nippon Zoki Pharmaceutical<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"The_Next_Wave_of_Competition_in_the_DEE_Market\"><\/span><strong>The Next Wave of Competition in the DEE Market<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"435\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/Competitive-Landscape-of-Emerging-Therapies-For-DEE-1024x435.webp\" alt=\"Competitive-Landscape-of-Emerging-Therapies-For-DEE\" class=\"wp-image-35650\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/Competitive-Landscape-of-Emerging-Therapies-For-DEE-1024x435.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/Competitive-Landscape-of-Emerging-Therapies-For-DEE-300x127.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/Competitive-Landscape-of-Emerging-Therapies-For-DEE-150x64.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/Competitive-Landscape-of-Emerging-Therapies-For-DEE-768x326.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/Competitive-Landscape-of-Emerging-Therapies-For-DEE-1536x652.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/Competitive-Landscape-of-Emerging-Therapies-For-DEE.webp 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>The investigational landscape includes several <a href=\"https:\/\/www.delveinsight.com\/report-store\/developmental-and-epileptic-encephalopathies-dee-pipeline-insight\">emerging DEE therapies<\/a> with differentiated mechanisms of action and targeted approaches. Key pipeline candidates include <strong>Relutrigine <\/strong>(Praxis Precision Medicines), <strong>Bexicaserin <\/strong>(Longboard Pharmaceuticals\/Lundbeck), <strong>Zorevunersen <\/strong>(Stoke Therapeutics), <strong>Apazunersen <\/strong>(Ultragenyx Pharmaceutical), <strong>Elsunersen <\/strong>(Praxis Precision Medicines), <strong>EPX-100<\/strong> (Harmony Biosciences), <strong>Rugonersen <\/strong>(Oak Hill Bio\/Roche), as well as additional assets such as <strong>Carisbamate <\/strong>(SK Life Science), <strong>Obudanersen <\/strong>(Ionis Pharmaceuticals), <strong>BMB-101<\/strong> (Bright Minds Biosciences), <strong>YCJ-01<\/strong> (Oils4Cure), <strong>Tricaprilin <\/strong>(Cerecin Neurosciences), and others. These therapies reflect increasing emphasis on precision medicine, genetic targeting, and novel pharmacological pathways.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/developmental-and-epileptic-encephalopathies-dee-market\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Developmental-and-Epileptic-Encephalopathies-Market-Outlook-1024x194.webp\" alt=\"\" class=\"wp-image-35637\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Developmental-and-Epileptic-Encephalopathies-Market-Outlook-1024x194.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Developmental-and-Epileptic-Encephalopathies-Market-Outlook-300x57.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Developmental-and-Epileptic-Encephalopathies-Market-Outlook-150x28.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Developmental-and-Epileptic-Encephalopathies-Market-Outlook-768x145.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Developmental-and-Epileptic-Encephalopathies-Market-Outlook-1536x291.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/07\/Developmental-and-Epileptic-Encephalopathies-Market-Outlook.webp 1584w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-faqs\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1654514197845\"><strong class=\"schema-faq-question\"><strong>What is Developmental Epileptic Encephalopathy?<\/strong><\/strong> <p class=\"schema-faq-answer\">Developmental and epileptic encephalopathy is considered to be a seizure disorder characterized by a type of seizure known as infantile spasms. The spasms usually appear before the age of 1.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1654514220903\"><strong class=\"schema-faq-question\"><strong>How is Epileptic Encephalopathy diagnosis done?<\/strong><\/strong> <p class=\"schema-faq-answer\">The EEG often evolves to atypical hypsarrhythmia which is transient or multifocal spike and sharp waves 3-4 months after the onset of the disease. The diagnosis of these epileptic encephalopathies begins with an EEG which should include both the sleep and wake states.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1654514240789\"><strong class=\"schema-faq-question\"><strong>Which companies are working in the Developmental Epileptic Encephalopathy market?<\/strong><\/strong> <p class=\"schema-faq-answer\">Leading pharma companies such as Epygenix, Xenon Pharmaceuticals, Longboard Pharmaceuticals, Stoke Therapeutics, Takeda\/Ovid Therapeutics, SK Life Science, Neurocrine Biosciences, Praxis Precision Medicines, Jazz Pharmaceuticals, Biocodex, Zogenix (Acquired by UCB), Lundbeck, Marinus Pharmaceuticals, Novartis, Aquestive Therapeutics, Supernus Pharmaceuticals, Lundbeck, Eisai Pharmaceuticals, GlaxoSmithKline, Meda Pharmaceuticals, Roche, Questcor Pharmaceuticals, Mallinckrodt Pharmaceuticals, BioPharm Solutions, and others are working on developing a novel approach to treating Developmental Epileptic Encephalopathy.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1654514261421\"><strong class=\"schema-faq-question\"><strong>Is Developmental and Epileptic Encephalopathy fatal?<\/strong><\/strong> <p class=\"schema-faq-answer\">Developmental and Epileptic Encephalopathy prognosis is very poor. Usually described as a progressive and untreatable disease, this rare disease is also associated with severe physical and cognitive disabilities and unexplained death.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Developmental and epileptic encephalopathies (DEEs) have evolved from symptom control toward precision neurology, with the market anchored by EPIDIOLEX (cannabidiol, Jazz Pharmaceuticals), initially approved in the US in 2018 for Dravet syndrome and Lennox\u2013Gastaut syndrome (LGS) and later expanded to tuberous sclerosis complex (TSC) in 2020, and FINTEPLA (fenfluramine, UCB), approved for Dravet syndrome in [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":17549,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[22276,22275,22277,2885,1494,2958],"industry":[17225],"therapeutic_areas":[17229,17245],"class_list":["post-17541","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-dee-market","tag-dee-therapies","tag-dee-treatment","tag-epidiolex","tag-epilepsy","tag-fintepla-zogenix","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Developmental and Epileptic Encephalopathy Market Therapies<\/title>\n<meta name=\"description\" content=\"The launch of therapies in the Developmental and Epileptic Encephalopathy Market like Epidiolex and Fintepla to transform treatment scenarios.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Developmental and Epileptic Encephalopathy Market Therapies\" \/>\n<meta property=\"og:description\" content=\"The launch of therapies in the Developmental and Epileptic Encephalopathy Market like Epidiolex and Fintepla to transform treatment scenarios.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-03T07:05:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-06T07:05:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06171114\/Epileptic-Encephalopathy.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Developmental and Epileptic Encephalopathy Market Therapies","description":"The launch of therapies in the Developmental and Epileptic Encephalopathy Market like Epidiolex and Fintepla to transform treatment scenarios.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla","og_locale":"en_US","og_type":"article","og_title":"Developmental and Epileptic Encephalopathy Market Therapies","og_description":"The launch of therapies in the Developmental and Epileptic Encephalopathy Market like Epidiolex and Fintepla to transform treatment scenarios.","og_url":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-07-03T07:05:32+00:00","article_modified_time":"2026-07-06T07:05:39+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06171114\/Epileptic-Encephalopathy.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#article","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla"},"author":{"name":"Sandeep Joshi","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"headline":"EPIDIOLEX and FINTEPLA in 2026: Commercial Anchors in a Precision DEE Pipeline","datePublished":"2026-07-03T07:05:32+00:00","dateModified":"2026-07-06T07:05:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla"},"wordCount":799,"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06171114\/Epileptic-Encephalopathy.jpg","keywords":["DEE Market","DEE Therapies","DEE Treatment","Epidiolex","Epilepsy","Fintepla (Zogenix)"],"articleSection":["Articles"],"inLanguage":"en-US","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.delveinsight.com\/blog\/#organization"}},{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla","url":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla","name":"Developmental and Epileptic Encephalopathy Market Therapies","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06171114\/Epileptic-Encephalopathy.jpg","datePublished":"2026-07-03T07:05:32+00:00","dateModified":"2026-07-06T07:05:39+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"The launch of therapies in the Developmental and Epileptic Encephalopathy Market like Epidiolex and Fintepla to transform treatment scenarios.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514197845"},{"@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514220903"},{"@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514240789"},{"@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514261421"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06171114\/Epileptic-Encephalopathy.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06171114\/Epileptic-Encephalopathy.jpg","width":772,"height":482,"caption":"Epileptic Encephalopathy"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514197845","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514197845","name":"What is Developmental Epileptic Encephalopathy?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Developmental and epileptic encephalopathy is considered to be a seizure disorder characterized by a type of seizure known as infantile spasms. The spasms usually appear before the age of 1.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514220903","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514220903","name":"How is Epileptic Encephalopathy diagnosis done?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The EEG often evolves to atypical hypsarrhythmia which is transient or multifocal spike and sharp waves 3-4 months after the onset of the disease. The diagnosis of these epileptic encephalopathies begins with an EEG which should include both the sleep and wake states.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514240789","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514240789","name":"Which companies are working in the Developmental Epileptic Encephalopathy market?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Leading pharma companies such as Epygenix, Xenon Pharmaceuticals, Longboard Pharmaceuticals, Stoke Therapeutics, Takeda\/Ovid Therapeutics, SK Life Science, Neurocrine Biosciences, Praxis Precision Medicines, Jazz Pharmaceuticals, Biocodex, Zogenix (Acquired by UCB), Lundbeck, Marinus Pharmaceuticals, Novartis, Aquestive Therapeutics, Supernus Pharmaceuticals, Lundbeck, Eisai Pharmaceuticals, GlaxoSmithKline, Meda Pharmaceuticals, Roche, Questcor Pharmaceuticals, Mallinckrodt Pharmaceuticals, BioPharm Solutions, and others are working on developing a novel approach to treating Developmental Epileptic Encephalopathy.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514261421","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/epidiolex-vs-fintepla#faq-question-1654514261421","name":"Is Developmental and Epileptic Encephalopathy fatal?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Developmental and Epileptic Encephalopathy prognosis is very poor. Usually described as a progressive and untreatable disease, this rare disease is also associated with severe physical and cognitive disabilities and unexplained death.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/06171114\/Epileptic-Encephalopathy-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DEE Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DEE Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DEE Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Epidiolex<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Epilepsy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Fintepla (Zogenix)<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">DEE Market<\/span>","<span class=\"advgb-post-tax-term\">DEE Therapies<\/span>","<span class=\"advgb-post-tax-term\">DEE Treatment<\/span>","<span class=\"advgb-post-tax-term\">Epidiolex<\/span>","<span class=\"advgb-post-tax-term\">Epilepsy<\/span>","<span class=\"advgb-post-tax-term\">Fintepla (Zogenix)<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 months ago","modified":"Updated 1 month ago"},"absolute_dates":{"created":"Posted on Jul 3, 2026","modified":"Updated on Jul 6, 2026"},"absolute_dates_time":{"created":"Posted on Jul 3, 2026 12:35 pm","modified":"Updated on Jul 6, 2026 12:35 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/17541","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=17541"}],"version-history":[{"count":6,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/17541\/revisions"}],"predecessor-version":[{"id":35651,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/17541\/revisions\/35651"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/17549"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=17541"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=17541"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=17541"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=17541"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=17541"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}